Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials

Fineline Cube Jan 6, 2026
Company Deals

Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases

Fineline Cube Jan 6, 2026
Company Deals

Touchstone Medical Partners with INSPUR to Advance Healthcare AI and Medical Robots

Fineline Cube Jan 6, 2026
Company Deals Drug

Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets

Fineline Cube Jan 6, 2026
Company Deals

Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform

Fineline Cube Jan 6, 2026
Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Fineline Cube Jan 6, 2026
Company Drug

Yifan Pharmaceutical’s F-652 Wins NMPA IND for GVHD Therapy

Fineline Cube Jan 6, 2026
Company Drug

Ark Biopharma’s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years

Fineline Cube Jan 6, 2026
Policy / Regulatory

Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation

Fineline Cube Aug 7, 2025

On August 6, 2025, seven Shanghai-based authorities jointly issued a notice titled “Several Measures on...

Company Drug

Hengrui’s Trastuzumab Rezetecan Granted FDA Orphan Drug Designation for Gastric Cancer Treatment

Fineline Cube Aug 7, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that it has received...

Company

Pfizer’s Q2 2025 Revenue Rises 10% Driven by Strong Biopharma Sales

Fineline Cube Aug 6, 2025

US-based Pfizer Inc. (NYSE: PFE) reported Q2 2025 financial results, revealing a 10% year-on-year (YOY)...

Company

Novo Nordisk Reports Strong H1 2025 Financial Results Driven by Semaglutide Sales

Fineline Cube Aug 6, 2025

Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced its financial results for the first...

Company Drug

Qyuns Therapeutics’ QX004N Enters Phase 3 Trials for Psoriasis and Crohn’s Disease

Fineline Cube Aug 6, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that QX004N, an interleukin-23 subunit p19...

Company Drug

Sino Biopharmaceutical’s TQC3302 Approved for COPD Maintenance Treatment Clinical Trials

Fineline Cube Aug 6, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed Category 2.3 modified new drug,...

Company Drug

Humanwell Healthcare Receives NMPA Approval for HW241045 IPF Clinical Trials

Fineline Cube Aug 6, 2025

China-based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its wholly-owned subsidiary, Humanwell Innovation...

Company Drug

Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy

Fineline Cube Aug 6, 2025

China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA)...

Company Drug

CSPC Pharmaceutical’s Semaglutide Injection NMPA Marketing Application Accepted

Fineline Cube Aug 6, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its semaglutide...

Company Drug

Hebei Senlang’s SENL103 CAR-T Therapy Approved for Refractory Generalized Myasthenia Gravis in China

Fineline Cube Aug 6, 2025

Hebei Senlang Biotechnology Co., Ltd. announced that its SENL103 autologous T-cell infusion has received clinical...

Company Deals

ChemPartner and Leado Pharma Sign Strategic Agreement to Advance New Drug R&D

Fineline Cube Aug 5, 2025

Shanghai ChemPartner Co., Ltd. (“ChemPartner”) and Shanghai Leado Pharma Co., Ltd. (“Leado Pharma”) have officially...

Company Deals

Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01

Fineline Cube Aug 5, 2025

China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng...

Company Medical Device

Gaush Meditech’s Frequency-Domain Biometer Gains Medical Device Registration in Jiangsu

Fineline Cube Aug 5, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) has recently obtained the medical device registration certificate for...

Company Drug

Sichuan Huiyu’s HY05350 Achieves First Patient Dosing in Phase I Trial for MSLN-Positive Tumors

Fineline Cube Aug 5, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that its wholly-owned subsidiary, Huiyu Haiyue,...

Company Drug

Zhaoke Ophthalmology’s TONO-i Gains NMPA Approval for Glaucoma Management in China

Fineline Cube Aug 5, 2025

China-based Zhaoke Ophthalmology Limited (HKG: 6622) announced that its innovative product, TONO-i, has received a...

Company Deals

Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau

Fineline Cube Aug 5, 2025

On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with...

Company Drug

Innovent Biologics’ IBI3032 Receives IND Approval From FDA and NMPA for GLP-1RA Clinical Trials

Fineline Cube Aug 5, 2025

China-based Innovent Biologics (HKG: 1801) announced that its self-developed oral small molecule GLP-1 receptor agonist...

Company Deals

Dr. Noah Biotech Collaborates with Thermo Fisher to Accelerate Rare Disease Treatments

Fineline Cube Aug 4, 2025

Korean AI drug discovery company Dr. Noah Biotech has announced the initiation of discussions with...

Company Deals

TenNor Therapeutics Submits Listing Application to Hong Kong Stock Exchange Main Board

Fineline Cube Aug 4, 2025

China-based TenNor Therapeutics (Suzhou) Limited announced the submission of its listing application to the Main...

Company Drug

FDA Clears Elevidys Gene Therapy After Investigating 8-Year-Old Boy’s Death

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) has completed its investigation into the death of...

Posts pagination

1 … 57 58 59 … 604

Recent updates

  • Yifan Pharmaceutical’s F-652 Wins NMPA IND for GVHD Therapy
  • NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs
  • Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials
  • Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases
  • Ark Biopharma’s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Yifan Pharmaceutical’s F-652 Wins NMPA IND for GVHD Therapy

Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Company Deals

Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials

Company Deals

Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.